Division of Sun Pharmaceutical Industries Ltd.
Latest From Basics GmbH
Ranbaxy is back in the news for GMP violations at its Dewas unit in India. Based on an inspection in June, this time Germany’s drug regulator has raised the red flag, citing deficiencies in design and clean room operations, among others. For its part, Ranbaxy clarified that it had decided to discontinue making injectable cephalosporins well before the joint inspection and that all its other facilities were cleared post the inspection.
- Generic Drugs
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Sun Pharmaceutical Industries Ltd.
- Senior Management
- Contact Info
Phone: (49) 0214 403 9912
Hemmelrather Weg 201
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.